Internal Reference Number: FOI_9600
Date Request Received: 11/08/2026 00:00:00
Date Request Replied To: 02/09/2026 00:00:00
This response was sent via: By Email
Request Summary: Haemophilia B and Von Willebrand Disease
Request Category: Researcher
| Question Number 1: How many patients has your Trust treated (for any medical condition) in the past 3 months with the following drugs: 鈥� Alprolix 鈥� BeneFIX 鈥� Haemate P 鈥� Idelvion 鈥� Refixia 鈥� Rixubis 鈥� Veyvondi 鈥� Voncento 鈥� Wilate 鈥� Willfact | |
| Answer To Question 1: 0 results | |
| Question Number 2: How many patients have been treated in the past 3 months with: 鈥� Marstacimab for Haemophilia B ONLY 鈥� Hemgenix 鈥� Desmopressin for Von Willebrand Disease ONLY 鈥� Tranexamic Acid for Von Willebrand Disease ONLY | |
| Answer To Question 2: 0 results | |
| Question Number 3: Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment: 鈥� Prophylactically 鈥� During surgery 鈥� On demand to treat bleeding episodes | |
| Answer To Question 3: 0 results | |
| Question Number 4: Of the patients that were treated with Voncento in the past 3 months, how many patients received treatment: 鈥� Prophylactically 鈥� During surgery 鈥� On demand to treat bleeding episodes | |
| Answer To Question 4: 0 results | |
| Question Number 5: How many patients are registered with your trust for the following diseases: 鈥� Haemophilia B 鈥� Von Willebrand Disease 鈥� Von Willebrand Disease - paediatric patients (age 17 or under) | |
| Answer To Question 5: Disease Patient Count Haemophilia B 8 Von Willebrand Disease 81 Von Willebrand Disease - Paediatric (17 or under) 7 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
